Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ohio Prevention and Treatment of Endometrial Cancer (OPTEC) Initiative: Universal Screening for DNA Mismatch Repair Deficiency and Personalized Cancer Treatment

NCT03460483 is registered in ClinicalTrials.gov with Ohio State University Comprehensive Cancer Center as lead sponsor.

NCT NCT03460483
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03460483 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ohio Prevention and Treatment of Endometrial Cancer (OPTEC) Initiative: Universal Screening for DNA Mismatch Repair Deficiency and Personalized Cancer Treatment
Lead sponsor
Ohio State University Comprehensive Cancer Center
Phase
Not applicable
Overall status
Completed
Start date
March 30, 2018
Completion date
June 15, 2025
Enrollment
1,001 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial adenocarcinoma, endometrial carcinoma, lynch syndrome, relatives